



BRITISH COLUMBIA
CENTRE *for* EXCELLENCE
in HIV/AIDS

B.C. HIV/AIDS Drug Treatment Program

Monthly Report

November 2015





HIV/AIDS Drug Treatment Program

Monthly Report

© 2016 BC Centre for Excellence in HIV/AIDS

DISCLAIMER: This document is published by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) as an overview of the activities of the BC-CfE's Drug Treatment Program. All information is generated from a live database maintained by the BC-CfE that houses data for clinical and virological outcome studies of patients receiving antiretroviral therapy.

This database is updated on a regular basis. Figures and tables provided in this Monthly Report represent the best estimates available at the time this document was generated.

Please be advised that information provided in this document is provided in good faith and is derived from sources believed to be accurate and up-to-date at the report's date of publication. The BC Centre for Excellence in HIV/AIDS nevertheless reserves the right to update this information at any time.

Information provided here at this time, is being provided freely, and no kind of agreement or contract is created between you and the authors. The authors cannot be responsible for any violations should you reproduce or republish the information contained herein.

Please note that the figures and graphs in this document are best viewed in colour.

BC Centre for Excellence in HIV/AIDS Drug Treatment Program

St. Paul's Hospital
608 - 1081 Burrard Street
Vancouver, BC
V6Z 1Y6

Tel: 604.682.8202
Fax: 604.806.9044

Physician Drug Hotline: 1.800.665.7677
St. Paul's Hospital Pharmacy Hotline: 1.888.511.6222
Website: www.cfenet.ubc.ca
Email: info@cfenet.ubc.ca

Funding for the BC Centre for Excellence in HIV/AIDS is provided through Pharmacare and the Provincial Health Services Authority (PHSA)



BRITISH COLUMBIA
CENTRE *for* EXCELLENCE
in HIV/AIDS



This document is best viewed in colour.
Drug definitions available in the back.



EXECUTIVE SUMMARY

A key component of the BC Centre for Excellence in HIV/AIDS' (BC-CfE) mandate is to monitor the impact of HIV/AIDS in British Columbia. The BC-CfE provides essential information to local health authorities, treating physicians, and the community at large on an ongoing basis. The HIV/AIDS Drug Treatment Program (DTP) Update is one example of the BC-CfE's commitment to HIV-infected persons throughout the Province of British Columbia.

The DTP distributes anti-HIV drugs at no cost to eligible British Columbians. The DTP Update provides an important overview of available anti-HIV drugs, common drug combinations and distribution of active DTP participants throughout the province.

DTP participants are typically followed at three-monthly intervals at which time routine blood sampling is performed. Information from all recipients is entered into a database, providing data for clinical and virological outcome studies of patients receiving antiretroviral therapy. These studies form the basis of ongoing revisions to the BC-CfE's treatment guidelines.





TABLE OF CONTENTS

1. List of Figures

- 1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants
- 1.5 BC-CfE Enrolment: New Antiretroviral Participants
- 1.6 Percent Distribution of Active Participants by CD4 Count
- 1.7 Percent Distribution of Inactive Participants by CD4 Count
- 1.8 Active and Inactive Participants
- 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by Ingredient
- 1.12 Distribution of Participants on Protease Inhibitor by Ingredient
- 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by Ingredient
- 1.14 Distribution of Participants on Non-Nucleosides by Ingredient
- 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by Ingredient
- 1.16 Distribution of Participants on Entry/Integrase Inhibitors by Ingredient
- 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by Ingredient
- 1.18 Baseline CD4 for Antiretroviral First Starts
- 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
- 1.20 Cumulative Resistance Testing Results by Resistance Category
- 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category

2. List of Tables

- 2.1 Duration of ARV treatment in the Province of BC, 1987-2012 (for HIV+ persons currently on treatment)
- 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program
- 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program
- 2.4 BC-CfE Enrolment
- 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 2.6 Number of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 2.7 Number of Participants on Protease Inhibitor by Ingredient
- 2.8 Number of Participants on Non-Nucleosides by Ingredient
- 2.9 Number of Participants on Entry/Integrase Inhibitors by Ingredient
- 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 2.11 Baseline CD4 for Antiretroviral First Starts
- 2.12 DTP Participants with PVL Measurement within previous five years, and never on ART





Table of Contents, cont'd...

3. Health Authority Maps

- 3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

4. Health Authority Tables

INTERIOR HEALTH

- 4.1 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries

FRASER HEALTH

- 4.4 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries

VANCOUVER COASTAL

- 4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries

VANCOUVER ISLAND

- 4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries

NORTHERN HEALTH

- 4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries

ABORIGINAL

- 4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

5. Appendix

- 5.1 Drug Names and Definitions






1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority

November 2015

N = 7020



Health Authority	Male	Female	All
FRASER	1297	382	1679
INTERIOR	359	91	450
NORTHERN	138	79	217
VANCOUVER COASTAL	3368	453	3821
VANCOUVER ISLAND	657	157	814
	5819	1162	6981
		Unknown/not stated:	39
		Total:	7020

Definitions:


On antiretroviral therapy defined as being on treatment in the current month

Unknown/not stated defined as being on treatment in the current month, and city of residence unknown






1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (November 2010 - November 2015)






1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (November 2010 - November 2015)






1.4 BC-CfE Enrollment: Net Number of New Antiretroviral Participants (November 2010 - November 2015)






1.5 BC-CfE Enrollment: New Antiretroviral Participants (November 2010 - November 2015)






1.6 Percent Distribution of Active Participants by CD4 Count (November 2010 - November 2015)






1.7 Percent Distribution of Inactive Participants by CD4 Count (November 2010 - November 2015)





1.8 Active and Inactive Participants (November 2010 - November 2015)






1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs (November 2010 - November 2015)






1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (November 2010 - November 2015)






1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by INGREDIENT

(November 2010 - November 2015)






1.12 Distribution of Participants on Protease Inhibitor by INGREDIENT (November 2010 - November 2015)






1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by INGREDIENT

(November 2010 - November 2015)






1.14 Distribution of Participants on Non-Nucleosides by INGREDIENT (November 2010 - November 2015)






1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by INGREDIENT

(November 2010 - November 2015)






1.16 Distribution of Participants on Entry/Integrase Inhibitors by INGREDIENT (November 2010 - November 2015)






1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by INGREDIENT

(November 2010 - November 2015)






1.18 Baseline CD4 for Antiretroviral First Starts (November 2010 - November 2015)






1.19 DTP Participants with PVL Measurement within previous five years, and never on ART (November 2010 - November 2015)






1.20 Cumulative Resistance Testing Results by Resistance Category (November 2010 - November 2015)





1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category (November 2010 - November 2015)





2.1 Duration of ARV treatment in the Province of BC, 1987-2015 (for HIV+ persons currently on treatment)

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
1987	24	4	0	4	4	850	4	<40	3
1988	24	8	0	8	8	565	8	<40	3
1989	23	55	2	57	51	530	53	<40	3
1990	21	64	1	65	60	505	64	<40	3
1991	21	38	3	41	38	600	41	<40	3
1992	21	69	6	75	58	560	74	<40	3
1993	20	148	16	164	147	550	158	<40	3
1994	19	98	13	111	87	560	106	<40	3
1995	19	128	23	151	122	545	142	<40	3
1996	17	378	60	438	379	590	427	<40	3
1997	15	312	42	354	315	610	342	<40	3
1998	14	221	45	266	211	540	248	<40	3
1999	14	182	42	224	185	570	215	<40	3
2000	15	144	38	182	156	580	175	<40	3
2001	14	131	38	169	138	550	162	<40	3
2002	13	140	32	172	136	585	161	<40	3
2003	12	178	37	215	188	585	207	<40	3
2004	11	176	47	223	182	565	212	<40	3
2005	10	211	53	264	219	590	253	<40	3
2006	9	218	48	266	211	530	252	<40	3
2007	8	279	56	335	280	575	320	<40	3
2008	7	318	76	394	321	620	374	<40	3
2009	6	351	78	429	366	630	410	<40	3
2010	5	322	75	397	336	650	375	<40	3
2011	4	369	75	444	377	620	418	<40	3
2012	3	312	70	382	323	680	362	<40	3
2013	2	306	75	381	296	600	351	<40	3
2014	1	326	60	386	322	670	370	<40	3
2015	1	350	52	402	357	540	393	<40	3
Total:		5836	1163	6999					

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased

Duration defined as cumulative years on ARV therapy, excluding periods of treatment interruption

Current CD4 and PVL tests defined as tests done in the last 6 months (most recent)

Current ARV defined as number of ARV drugs in the current regimen





2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program

MON-YYYY	# of patients	Median # of therapy days	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2014	6557	782	2429	<40	2151	560
FEB-2014	6570	780	1895	<40	1656	550
MAR-2014	6598	786	2156	<40	1927	550
APR-2014	6611	786	2126	<40	1874	560
MAY-2014	6677	768	2120	<40	1887	560
JUN-2014	6644	783	1994	<40	1768	550
JUL-2014	6682	778	2179	<40	1930	550
AUG-2014	6702	774	2026	<40	1806	570
SEP-2014	6730	769	2284	<40	2005	550
OCT-2014	6760	760	2250	<40	1958	570
NOV-2014	6758	756	1920	<40	1706	580
DEC-2014	6769	765	1896	<40	1689	580
JAN-2015	6743	760	2430	<40	2112	580
FEB-2015	6792	753	1978	<40	1729	570
MAR-2015	6837	747	2173	<40	1897	570
APR-2015	6850	739	2149	<40	1907	580
MAY-2015	6890	739	2032	<40	1786	560
JUN-2015	6905	740	2255	<40	1957	580
JUL-2015	6931	738	2039	<40	1793	580
AUG-2015	6929	750	2076	<40	1762	580
SEP-2015	6937	745	2270	<40	1926	580
OCT-2015	6972	737	2108	<40	1739	590
NOV-2015	7020	722	2064	<40	1708	580

Definitions:

Active patient defined as being on ARV treatment in the specified month

Therapy days defined as number of consecutive days on ARV treatment (most recent uninterrupted period)

PVL and CD4 tests defined as tests done in the specified month





2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program

MON-YYYY	# of patients	Median # days of off therapy	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2014	1410	2265	100	6683	76	285
FEB-2014	1431	2152	73	496	67	490
MAR-2014	1433	2169	114	3726	99	340
APR-2014	1443	2144	112	128	90	400
MAY-2014	1414	2308	90	617	76	350
JUN-2014	1467	2052	96	423	82	380
JUL-2014	1459	2111	95	982	76	355
AUG-2014	1452	2158	87	208	72	365
SEP-2014	1451	2180	103	866	89	390
OCT-2014	1439	2250	84	257	62	395
NOV-2014	1452	2234	74	3945	64	400
DEC-2014	1474	2172	93	557	72	340
JAN-2015	1512	2044	105	1364	85	310
FEB-2015	1495	2119	101	78	86	380
MAR-2015	1469	2263	101	56	92	405
APR-2015	1474	2262	83	2239	68	465
MAY-2015	1456	2372	73	148	60	430
JUN-2015	1473	2305	95	97	89	430
JUL-2015	1466	2354	70	768	53	380
AUG-2015	1477	2322	81	2496	73	440
SEP-2015	1496	2282	87	128	75	345
OCT-2015	1477	2383	73	<40	57	380
NOV-2015	1458	2484	86	364	69	480

Definitions:

Inactive patient defined as not deceased, not being on ARV treatment in the specified month (but previously treated with ARVs)

Days off therapy defined as number of days elapsed since last ARV treatment

PVL and CD4 tests defined as tests done in the specified month





2.4 BC-CfE Enrollment

MON-YYYY	Currently on ARV Therapy	Currently off ARV Therapy	Deceased	First Starts	Experienced Starts	New Inactive	Net Change	Cumulative Patients
JAN-2014	6539	1410	2	30	144	136	35	11493
FEB-2014	6548	1431	9	40	139	159	9	11537
MAR-2014	6573	1433	9	36	151	146	25	11581
APR-2014	6587	1443	5	27	159	161	14	11617
MAY-2014	6646	1414	14	38	191	152	59	11667
JUN-2014	6618	1467	7	24	142	183	-28	11705
JUL-2014	6659	1459	8	34	176	159	41	11749
AUG-2014	6682	1452	6	18	165	150	23	11781
SEP-2014	6713	1451	2	25	168	158	31	11820
OCT-2014	6738	1439	7	21	159	146	25	11847
NOV-2014	6732	1452	12	19	135	144	-6	11871
DEC-2014	6744	1474	7	39	136	150	12	11920
JAN-2015	6710	1512	13	24	149	187	-34	11955
FEB-2015	6761	1495	7	36	187	162	51	12007
MAR-2015	6812	1469	7	29	174	143	51	12047
APR-2015	6812	1474	15	28	169	172	0	12083
MAY-2015	6853	1456	9	33	171	148	41	12124
JUN-2015	6876	1473	5	36	155	161	23	12171
JUL-2015	6912	1466	5	25	165	147	36	12209
AUG-2015	6912	1477	7	20	145	157	0	12240
SEP-2015	6917	1496	9	34	157	175	5	12283
OCT-2015	6948	1477	15	25	170	145	31	12320
NOV-2015	6999	1458	7	29	182	152	51	12361

Definitions:

Currently on ARV Therapy defined as being on ARV treatment in the specified month, and not deceased/moved out of BC

Currently off ARV Therapy defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARVs in the past

Deceased defined as deceased in the specified month, and being on ARV treatment in the previous month

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Experienced Starts defined as starting ARV treatment in the specified month, but previously being treated with ARVs

New Inactive defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARV treatment in the previous month

Net Change is defined as difference between ARV starts (First and Experienced) and ARV stops (Deceased/Moved out of BC and New Inactive)





2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs

MON-YYYY	Less than 3 Drugs	3 Drugs	4 Drugs	5 or more Drugs	All ARV	Less than 3 Drugs%	3 Drugs%	4 Drugs%	5 or more Drugs%	Total%
JAN-2014	47	6025	414	71	6557	0.72%	91.89%	6.31%	1.08%	100.00%
FEB-2014	50	6034	418	68	6570	0.76%	91.84%	6.36%	1.04%	100.00%
MAR-2014	50	6054	424	70	6598	0.76%	91.76%	6.43%	1.06%	100.00%
APR-2014	46	6067	422	76	6611	0.70%	91.77%	6.38%	1.15%	100.00%
MAY-2014	47	6138	418	74	6677	0.70%	91.93%	6.26%	1.11%	100.00%
JUN-2014	50	6107	416	71	6644	0.75%	91.92%	6.26%	1.07%	100.00%
JUL-2014	47	6147	415	73	6682	0.70%	91.99%	6.21%	1.09%	100.00%
AUG-2014	47	6170	414	72	6703	0.70%	92.05%	6.18%	1.07%	100.00%
SEP-2014	50	6185	424	71	6730	0.74%	91.90%	6.30%	1.05%	100.00%
OCT-2014	47	6206	434	73	6760	0.70%	91.80%	6.42%	1.08%	100.00%
NOV-2014	50	6214	424	70	6758	0.74%	91.95%	6.27%	1.04%	100.00%
DEC-2014	45	6229	421	74	6769	0.66%	92.02%	6.22%	1.09%	100.00%
JAN-2015	47	6182	440	74	6743	0.70%	91.68%	6.53%	1.10%	100.00%
FEB-2015	47	6221	451	73	6792	0.69%	91.59%	6.64%	1.07%	100.00%
MAR-2015	47	6287	436	67	6837	0.69%	91.96%	6.38%	0.98%	100.00%
APR-2015	46	6302	435	67	6850	0.67%	92.00%	6.35%	0.98%	100.00%
MAY-2015	47	6344	431	68	6890	0.68%	92.08%	6.26%	0.99%	100.00%
JUN-2015	49	6337	447	72	6905	0.71%	91.77%	6.47%	1.04%	100.00%
JUL-2015	46	6364	454	67	6931	0.66%	91.82%	6.55%	0.97%	100.00%
AUG-2015	48	6365	446	70	6929	0.69%	91.86%	6.44%	1.01%	100.00%
SEP-2015	47	6385	441	64	6937	0.68%	92.04%	6.36%	0.92%	100.00%
OCT-2015	49	6416	443	64	6972	0.70%	92.03%	6.35%	0.92%	100.00%
NOV-2015	53	6455	445	67	7020	0.75%	91.95%	6.34%	0.95%	100.00%

Definitions:

Number of Drugs is calculated as number of individual drugs in ARV Therapy (excluding low dose ritonavir used for boosting a protease inhibitor)





2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT

	Lamivudine		Abacavir		Zidovudine		Stavudine		Didanosine		Emtricitabine		Tenofovir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2014	8 19%	2381 37%	7 17%	1994 31%	0 0%	144 2%	0 0%	25 0%	0 0%	17 0%	33 79%	3862 61%	36 86%	4269 67%
FEB-2014	7 16%	2383 37%	7 16%	1992 31%	0 0%	140 2%	0 0%	25 0%	0 0%	16 0%	37 84%	3880 61%	37 84%	4286 67%
MAR-2014	7 16%	2386 37%	6 14%	2007 31%	0 0%	140 2%	0 0%	22 0%	0 0%	13 0%	37 84%	3893 61%	38 86%	4298 67%
APR-2014	3 8%	2396 37%	3 8%	2022 32%	0 0%	137 2%	0 0%	22 0%	0 0%	12 0%	33 92%	3904 61%	33 92%	4301 67%
MAY-2014	17 34%	2434 38%	16 32%	2058 32%	1 2%	137 2%	0 0%	21 0%	0 0%	13 0%	33 66%	3929 61%	33 66%	4325 67%
JUN-2014	8 21%	2430 38%	9 24%	2062 32%	0 0%	130 2%	0 0%	20 0%	1 3%	13 0%	29 76%	3905 61%	29 76%	4293 67%
JUL-2014	13 30%	2462 38%	11 25%	2095 32%	1 2%	129 2%	0 0%	22 0%	0 0%	13 0%	31 70%	3918 60%	32 73%	4298 66%
AUG-2014	7 23%	2474 38%	7 23%	2108 32%	0 0%	132 2%	0 0%	21 0%	0 0%	11 0%	24 77%	3912 60%	24 77%	4286 66%
SEP-2014	15 38%	2517 39%	12 31%	2146 33%	3 8%	136 2%	0 0%	18 0%	0 0%	12 0%	24 62%	3905 60%	24 62%	4285 66%
OCT-2014	10 37%	2545 39%	9 33%	2173 33%	0 0%	134 2%	0 0%	18 0%	0 0%	12 0%	17 63%	3905 60%	17 63%	4286 65%
NOV-2014	6 25%	2547 39%	6 25%	2183 33%	0 0%	129 2%	0 0%	18 0%	0 0%	12 0%	17 71%	3895 59%	19 79%	4268 65%
DEC-2014	13 27%	2576 39%	9 18%	2205 34%	3 6%	129 2%	0 0%	19 0%	0 0%	11 0%	36 73%	3873 59%	37 76%	4245 65%
JAN-2015	10 29%	2584 40%	10 29%	2221 34%	0 0%	127 2%	0 0%	19 0%	0 0%	11 0%	25 71%	3848 59%	25 71%	4212 64%
FEB-2015	8 15%	2593 39%	8 15%	2228 34%	0 0%	127 2%	0 0%	19 0%	0 0%	9 0%	44 85%	3883 59%	44 85%	4246 64%
MAR-2015	10 25%	2610 39%	10 25%	2253 34%	0 0%	124 2%	0 0%	18 0%	0 0%	10 0%	30 75%	3916 59%	30 75%	4272 64%
APR-2015	10 29%	2626 40%	10 29%	2267 34%	0 0%	117 2%	0 0%	16 0%	0 0%	9 0%	24 69%	3917 59%	24 69%	4273 64%
MAY-2015	8 20%	2640 40%	7 18%	2282 34%	0 0%	118 2%	0 0%	14 0%	0 0%	9 0%	32 80%	3931 59%	33 83%	4285 64%
JUN-2015	10 21%	2636 39%	10 21%	2290 34%	0 0%	115 2%	0 0%	15 0%	0 0%	9 0%	37 79%	3948 59%	37 79%	4299 64%
JUL-2015	4 11%	2660 40%	4 11%	2314 34%	0 0%	111 2%	0 0%	14 0%	0 0%	9 0%	34 89%	3950 59%	34 89%	4300 64%
AUG-2015	13 42%	2678 40%	12 39%	2337 35%	1 3%	111 2%	0 0%	12 0%	0 0%	9 0%	18 58%	3945 59%	18 58%	4285 64%
SEP-2015	17 40%	2721 40%	15 35%	2378 35%	0 0%	107 2%	1 2%	13 0%	0 0%	6 0%	26 60%	3920 58%	26 60%	4261 63%
OCT-2015	11 30%	2754 41%	10 27%	2410 36%	0 0%	103 2%	0 0%	13 0%	0 0%	8 0%	26 70%	3914 58%	27 73%	4253 63%
NOV-2015	17 41%	2793 41%	15 37%	2448 36%	1 2%	102 2%	0 0%	13 0%	0 0%	8 0%	24 59%	3918 58%	25 61%	4248 63%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.7 Number of Participants on Protease Inhibitor by INGREDIENT

	(fos)amprenavir		Atazanavir		Darunavir		Lopinavir		Nelfinavir		Ritonavir		Saquinavir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2014	0 0%	19 1%	10 59%	2306 65%	7 41%	738 21%	0 0%	471 13%	0 0%	6 0%	0 0%	3 0%	0 0%	28 1%
FEB-2014	0 0%	19 1%	12 57%	2287 64%	7 33%	761 21%	2 10%	470 13%	0 0%	4 0%	0 0%	2 0%	0 0%	27 1%
MAR-2014	0 0%	18 1%	8 47%	2266 64%	7 41%	788 22%	2 12%	475 13%	0 0%	5 0%	0 0%	2 0%	0 0%	26 1%
APR-2014	0 0%	18 1%	11 52%	2259 63%	10 48%	811 23%	0 0%	468 13%	0 0%	3 0%	0 0%	2 0%	0 0%	26 1%
MAY-2014	0 0%	16 0%	7 41%	2249 64%	9 53%	815 23%	1 6%	456 13%	0 0%	4 0%	0 0%	3 0%	0 0%	25 1%
JUN-2014	0 0%	16 0%	5 31%	2198 63%	9 56%	831 24%	2 13%	449 13%	0 0%	5 0%	0 0%	3 0%	0 0%	25 1%
JUL-2014	0 0%	15 0%	10 59%	2182 63%	6 35%	851 24%	1 6%	433 12%	0 0%	5 0%	0 0%	1 0%	0 0%	26 1%
AUG-2014	0 0%	14 0%	2 20%	2153 62%	8 80%	856 25%	0 0%	425 12%	0 0%	5 0%	0 0%	1 0%	0 0%	24 1%
SEP-2014	0 0%	14 0%	4 31%	2139 62%	6 46%	868 25%	3 23%	424 12%	0 0%	5 0%	0 0%	1 0%	0 0%	21 1%
OCT-2014	0 0%	14 0%	3 30%	2132 62%	5 50%	889 26%	2 20%	407 12%	0 0%	4 0%	0 0%	1 0%	0 0%	19 1%
NOV-2014	0 0%	15 0%	10 83%	2106 62%	2 17%	893 26%	0 0%	397 12%	0 0%	5 0%	0 0%	1 0%	0 0%	19 1%
DEC-2014	0 0%	13 0%	7 32%	2074 61%	12 55%	922 27%	3 14%	385 11%	0 0%	5 0%	0 0%	1 0%	0 0%	19 1%
JAN-2015	0 0%	12 0%	6 50%	2030 60%	6 50%	932 28%	0 0%	383 11%	0 0%	4 0%	0 0%	1 0%	0 0%	18 1%
FEB-2015	0 0%	10 0%	8 31%	2031 60%	18 69%	960 28%	0 0%	380 11%	0 0%	5 0%	0 0%	1 0%	0 0%	17 1%
MAR-2015	0 0%	11 0%	8 47%	2044 60%	8 47%	971 29%	0 0%	375 11%	1 6%	6 0%	0 0%	1 0%	0 0%	17 0%
APR-2015	0 0%	12 0%	7 33%	2026 60%	14 67%	990 29%	0 0%	364 11%	0 0%	6 0%	0 0%	1 0%	0 0%	18 1%
MAY-2015	0 0%	12 0%	10 63%	2003 59%	6 38%	1020 30%	0 0%	360 11%	0 0%	4 0%	0 0%	1 0%	0 0%	19 1%
JUN-2015	0 0%	11 0%	8 44%	1969 58%	10 56%	1037 31%	0 0%	359 11%	0 0%	5 0%	0 0%	1 0%	0 0%	18 1%
JUL-2015	0 0%	10 0%	1 7%	1961 58%	11 79%	1051 31%	1 7%	352 10%	0 0%	5 0%	0 0%	1 0%	1 7%	19 1%
AUG-2015	0 0%	11 0%	1 9%	1947 58%	7 64%	1057 31%	3 27%	346 10%	0 0%	4 0%	0 0%	1 0%	0 0%	18 1%
SEP-2015	0 0%	11 0%	4 24%	1916 57%	12 71%	1065 32%	1 6%	339 10%	0 0%	3 0%	0 0%	1 0%	0 0%	17 1%
OCT-2015	0 0%	10 0%	5 31%	1905 57%	10 63%	1092 33%	1 6%	332 10%	0 0%	4 0%	0 0%	1 0%	0 0%	17 1%
NOV-2015	0 0%	10 0%	5 31%	1884 56%	9 56%	1108 33%	2 13%	329 10%	0 0%	4 0%	0 0%	1 0%	0 0%	17 1%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.7 Number of Participants on Protease Inhibitor by INGREDIENT (continued)

	Tipranavir			
	Initial		All	
JAN-2014	0	0%	1	0%
FEB-2014	0	0%	0	0%
MAR-2014	0	0%	1	0%
APR-2014	0	0%	1	0%
MAY-2014	0	0%	1	0%
JUN-2014	0	0%	1	0%
JUL-2014	0	0%	1	0%
AUG-2014	0	0%	1	0%
SEP-2014	0	0%	1	0%
OCT-2014	0	0%	1	0%
NOV-2014	0	0%	1	0%
DEC-2014	0	0%	1	0%
JAN-2015	0	0%	1	0%
FEB-2015	0	0%	1	0%
MAR-2015	0	0%	1	0%
APR-2015	0	0%	1	0%
MAY-2015	0	0%	1	0%
JUN-2015	0	0%	1	0%
JUL-2015	0	0%	1	0%
AUG-2015	0	0%	1	0%
SEP-2015	0	0%	1	0%
OCT-2015	0	0%	1	0%
NOV-2015	0	0%	1	0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.8 Number of Participants on Non-Nucleosides by INGREDIENT

	Efavirenz		Etravirine		Nevirapine		Ralpivirine	
	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2014	12 80%	1342 48%	1 7%	304 11%	0 0%	948 34%	2 13%	233 8%
FEB-2014	12 71%	1343 48%	0 0%	305 11%	0 0%	942 33%	5 29%	244 9%
MAR-2014	10 71%	1320 47%	0 0%	298 11%	0 0%	943 34%	4 29%	253 9%
APR-2014	4 57%	1304 47%	0 0%	302 11%	1 14%	941 34%	2 29%	260 9%
MAY-2014	5 71%	1298 46%	0 0%	299 11%	0 0%	938 34%	2 29%	263 9%
JUN-2014	4 50%	1280 46%	1 13%	303 11%	1 13%	926 34%	2 25%	258 9%
JUL-2014	8 73%	1261 46%	0 0%	304 11%	1 9%	927 34%	2 18%	257 9%
AUG-2014	11 85%	1260 46%	1 8%	304 11%	0 0%	928 34%	1 8%	254 9%
SEP-2014	8 73%	1254 46%	0 0%	300 11%	2 18%	928 34%	1 9%	251 9%
OCT-2014	3 60%	1231 45%	2 40%	306 11%	0 0%	921 34%	0 0%	255 9%
NOV-2014	2 100%	1207 45%	0 0%	302 11%	0 0%	911 34%	0 0%	252 9%
DEC-2014	8 62%	1189 45%	0 0%	304 11%	1 8%	901 34%	4 31%	254 10%
JAN-2015	6 75%	1174 45%	0 0%	306 12%	0 0%	900 34%	2 25%	254 10%
FEB-2015	4 50%	1169 45%	0 0%	306 12%	0 0%	892 34%	4 50%	251 10%
MAR-2015	7 88%	1167 45%	0 0%	303 12%	0 0%	889 34%	1 13%	255 10%
APR-2015	4 67%	1148 44%	1 17%	305 12%	0 0%	888 34%	1 17%	259 10%
MAY-2015	7 58%	1139 44%	1 8%	309 12%	0 0%	887 34%	4 33%	260 10%
JUN-2015	2 29%	1133 44%	0 0%	317 12%	0 0%	877 34%	5 71%	262 10%
JUL-2015	8 89%	1122 44%	0 0%	311 12%	0 0%	880 34%	1 11%	260 10%
AUG-2015	4 80%	1104 43%	0 0%	307 12%	0 0%	879 35%	1 20%	253 10%
SEP-2015	8 89%	1097 43%	1 11%	305 12%	0 0%	874 35%	0 0%	256 10%
OCT-2015	2 50%	1086 43%	0 0%	312 12%	1 25%	867 34%	1 25%	251 10%
NOV-2015	4 67%	1076 43%	0 0%	312 12%	0 0%	865 35%	2 33%	254 10%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT

	Dolutegravir		Elvitegravir		Maraviroc		Raltegravir		Enfuvirtide	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2014	4 31%	13 1%	6 46%	154 13%	0 0%	79 7%	3 23%	926 81%	0 0%	2 0%
FEB-2014	1 17%	19 2%	5 83%	163 14%	0 0%	77 7%	0 0%	939 81%	0 0%	2 0%
MAR-2014	1 8%	31 3%	8 62%	179 15%	0 0%	78 6%	4 31%	947 79%	0 0%	2 0%
APR-2014	4 50%	78 6%	2 25%	198 16%	0 0%	82 7%	2 25%	953 76%	0 0%	2 0%
MAY-2014	16 64%	138 10%	6 24%	220 16%	0 0%	80 6%	3 12%	948 71%	0 0%	1 0%
JUN-2014	7 47%	187 13%	7 47%	237 17%	0 0%	76 5%	1 7%	930 67%	0 0%	2 0%
JUL-2014	10 59%	247 17%	5 29%	252 17%	0 0%	74 5%	2 12%	932 64%	0 0%	2 0%
AUG-2014	6 55%	298 20%	3 27%	267 18%	0 0%	74 5%	2 18%	919 61%	0 0%	2 0%
SEP-2014	7 47%	355 22%	4 27%	281 18%	0 0%	73 5%	4 27%	919 58%	0 0%	1 0%
OCT-2014	7 47%	406 25%	6 40%	309 19%	0 0%	71 4%	2 13%	906 55%	0 0%	1 0%
NOV-2014	5 45%	452 27%	5 45%	325 19%	0 0%	70 4%	1 9%	893 53%	0 0%	1 0%
DEC-2014	11 65%	500 29%	6 35%	335 19%	0 0%	72 4%	0 0%	888 51%	0 0%	1 0%
JAN-2015	13 72%	541 30%	4 22%	349 19%	1 6%	68 4%	1 6%	879 49%	0 0%	1 0%
FEB-2015	14 58%	577 31%	8 33%	355 19%	0 0%	74 4%	2 8%	880 48%	0 0%	1 0%
MAR-2015	9 50%	600 32%	5 28%	367 20%	0 0%	69 4%	4 22%	869 47%	0 0%	2 0%
APR-2015	7 50%	628 33%	4 29%	373 20%	2 14%	67 4%	1 7%	862 45%	0 0%	2 0%
MAY-2015	11 65%	665 34%	4 24%	382 20%	1 6%	70 4%	2 12%	864 44%	0 0%	2 0%
JUN-2015	15 56%	712 35%	8 30%	396 20%	0 0%	72 4%	4 15%	875 43%	0 0%	1 0%
JUL-2015	11 58%	748 37%	4 21%	404 20%	0 0%	71 3%	4 21%	866 42%	0 0%	1 0%
AUG-2015	12 71%	785 38%	4 24%	413 20%	0 0%	70 3%	1 6%	855 41%	0 0%	1 0%
SEP-2015	17 81%	851 40%	2 10%	414 19%	0 0%	65 3%	2 10%	857 40%	0 0%	1 0%
OCT-2015	14 70%	891 40%	6 30%	437 20%	0 0%	65 3%	0 0%	852 39%	0 0%	1 0%
NOV-2015	15 71%	938 42%	6 29%	440 20%	0 0%	67 3%	0 0%	854 38%	0 0%	1 0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class

MON-YYYY	Boosted PI + 2 NRTIs		NNRTI + 2 NRTIs		Integrase + 2 NRTIs		Un-boosted PI + 2 NRTIs		MDRT		Other	
	n	%	n	%	n	%	n	%	n	%	n	%
JAN-2014	2572	39.23	2316	35.32	551	8.40	191	2.91	71	1.08	856	13.05
FEB-2014	2555	38.89	2319	35.30	579	8.81	189	2.88	68	1.04	860	13.09
MAR-2014	2560	38.80	2310	35.01	606	9.18	188	2.85	70	1.06	864	13.09
APR-2014	2542	38.45	2288	34.61	653	9.88	192	2.90	76	1.15	860	13.01
MAY-2014	2537	38.00	2275	34.07	739	11.07	193	2.89	74	1.11	859	12.87
JUN-2014	2502	37.66	2246	33.80	782	11.77	183	2.75	71	1.07	860	12.94
JUL-2014	2493	37.31	2235	33.45	840	12.57	191	2.86	73	1.09	850	12.72
AUG-2014	2465	36.77	2232	33.30	890	13.28	186	2.77	72	1.07	858	12.80
SEP-2014	2437	36.21	2221	33.00	946	14.06	187	2.78	71	1.05	868	12.90
OCT-2014	2417	35.75	2190	32.40	1008	14.91	192	2.84	73	1.08	880	13.02
NOV-2014	2419	35.79	2159	31.95	1056	15.63	184	2.72	70	1.04	870	12.87
DEC-2014	2398	35.43	2144	31.67	1103	16.29	185	2.73	74	1.09	865	12.78
JAN-2015	2348	34.82	2124	31.50	1137	16.86	179	2.65	74	1.10	881	13.07
FEB-2015	2364	34.81	2111	31.08	1176	17.31	178	2.62	73	1.07	890	13.10
MAR-2015	2398	35.07	2112	30.89	1203	17.60	184	2.69	67	0.98	873	12.77
APR-2015	2392	34.92	2095	30.58	1239	18.09	184	2.69	67	0.98	873	12.74
MAY-2015	2399	34.82	2094	30.39	1277	18.53	179	2.60	68	0.99	873	12.67
JUN-2015	2369	34.31	2078	30.09	1324	19.17	171	2.48	72	1.04	891	12.90
JUL-2015	2375	34.27	2068	29.84	1353	19.52	170	2.45	67	0.97	898	12.96
AUG-2015	2369	34.19	2044	29.50	1384	19.97	167	2.41	70	1.01	895	12.92
SEP-2015	2331	33.60	2033	29.31	1451	20.92	167	2.41	64	0.92	891	12.84
OCT-2015	2336	33.51	2007	28.79	1495	21.44	167	2.40	64	0.92	903	12.95
NOV-2015	2329	33.18	2014	28.69	1540	21.94	160	2.28	67	0.95	910	12.96

Definitions:

n is number of participants on the specified regimen class in the specified month
 % is ratio of n and total number of participants on ART in the specified month





2.11 Baseline CD4 for Antiretroviral First Starts

MON-YYYY	# of First Starts	# of Pts with CD4 < 100	# of Pts with CD4: 100-199	# of Pts with CD4: 200-349	# of Pts with CD4: 350-500	# of Pts with CD4 > 500	Median CD4
JAN-2014	30	6	2	9	4	9	300
FEB-2014	40	4	7	10	4	13	316
MAR-2014	36	2	2	9	10	13	405
APR-2014	27	3	6	2	5	10	355
MAY-2014	38	2	4	3	10	18	500
JUN-2014	24	3	1	6	6	7	400
JUL-2014	34	3	7	7	5	13	350
AUG-2014	18	3	1	3	5	6	410
SEP-2014	25	5	3	3	4	9	395
OCT-2014	21	1	4	6	4	5	315
NOV-2014	19	5	1	0	4	8	475
DEC-2014	39	3	5	7	11	13	401
JAN-2015	24	2	2	8	3	9	370
FEB-2015	36	3	3	9	3	16	469
MAR-2015	29	2	5	5	8	7	386
APR-2015	28	8	3	4	3	10	335
MAY-2015	33	4	6	9	5	8	290
JUN-2015	36	6	2	8	8	11	370
JUL-2015	25	6	2	2	6	7	380
AUG-2015	20	2	3	4	2	8	460
SEP-2015	34	8	1	5	3	15	451
OCT-2015	25	5	2	3	4	9	430
NOV-2015	29	5	1	5	6	10	400

Definitions:

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Baseline CD4 is defined as most recent CD4 test before ARV start





2.12 DTP Participants with PVL Measurement within previous five years, and never on ART

MON-YYYY	# of Participants with PVL test	# of Participants with PVL test, and never on ART
JAN-2014	10027	2578
FEB-2014	10049	2571
MAR-2014	10062	2557
APR-2014	10092	2560
MAY-2014	10116	2554
JUN-2014	10151	2564
JUL-2014	10163	2552
AUG-2014	10212	2586
SEP-2014	10254	2596
OCT-2014	10276	2604
NOV-2014	10307	2626
DEC-2014	10348	2630
JAN-2015	10390	2660
FEB-2015	10436	2667
MAR-2015	10475	2676
APR-2015	10495	2688
MAY-2015	10549	2712
JUN-2015	10635	2759
JUL-2015	10704	2807
AUG-2015	10770	2862
SEP-2015	10855	2915
OCT-2015	10907	2955
NOV-2015	10974	2996

Definitions:

Patients with PVL test are defined as having at least one PVL test within previous five years, and not reported deceased/moved
Never on ART are subset of patients with PVL test, and not being treated with ARVs on or before specified month







3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
November 2015

N = 7020

BY HEALTH SERVICES DELIVERY AREA



BY HEALTH AUTHORITY







3.2 Distribution of HIV/AIDS Drug Treatment Program Active Participants

November 2015

INTERIOR HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



KELOWNA BY POSTAL CODE







3.3 Distribution of HIV/AIDS Drug Treatment Program Active Participants

November 2015

FRASER HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



SURREY BY POSTAL CODE







3.4 Distribution of HIV/AIDS Drug Treatment Program Active Participants

November 2015

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VANCOUVER BY POSTAL CODE







3.5 Distribution of HIV/AIDS Drug Treatment Program Active Participants

November 2015

VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VICTORIA BY POSTAL CODE







3.6 Distribution of HIV/AIDS Drug Treatment Program Active Participants

November 2015

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE





4.1 Distribution of Participants in BC-CfE Registries by Age and Gender INTERIOR Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
EAST KOOTENAY	35-49	12	14	9
	50+	21	31	15
	Total HSDA:	33	45	24
KOOTENAY BOUNDARY	0-19	1	1	1
	20-34	4	4	3
	35-49	18	24	13
	50+	46	61	34
	Total HSDA:	69	90	51
OKANAGAN	0-19	4	4	3
	20-34	22	23	17
	35-49	93	108	67
	50+	193	279	155
	Total HSDA:	312	414	242
THOMPSON/CARIBOO/ SHUSWAP	0-19	5	5	0
	20-34	19	19	14
	35-49	56	69	43
	50+	90	130	76
	Total HSDA:	170	223	133
Total HA:		584	772	450

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	10	10	4
	20-34	45	46	34
	35-49	179	215	132
	50+	350	501	280
Total HA:		584	772	450

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	453	612	359
Female	131	160	91

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	450	53	560	35

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
INTERIOR Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
EAST KOOTENAY	10 years or more	16	10
	5 years or more	7	5
	<5 years	10	9
	Total HSDA:	33	24
KOOTENAY BOUNDARY	10 years or more	33	23
	5 years or more	19	15
	<5 years	17	13
	Total HSDA:	69	51
OKANAGAN	10 years or more	168	120
	5 years or more	72	61
	<5 years	72	61
	Total HSDA:	312	242
THOMPSON/CARIBOO/ SHUSWAP	10 years or more	87	61
	5 years or more	35	33
	<5 years	48	39
	Total HSDA:	170	133
Total HA:		584	450

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	304	214
	5 years or more	133	114
	<5 years	147	122
Total HA:		584	450

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries INTERIOR Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
EAST KOOTENAY	35	49	13	22
KOOTENAY BOUNDARY	61	109	26	42
OKANAGAN	191	651	66	229
THOMPSON/CARIBOO/SHUSWAP	124	406	45	102
Total:	411	1215	150	395

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
EAST KOOTENAY	1
KOOTENAY BOUNDARY	12
OKANAGAN	41
THOMPSON/CARIBOO/SHUSWAP	38
Total:	92

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.4 Distribution of Participants in BC-CfE Registries by Age and Gender FRASER Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
FRASER EAST	0-19	7	7	4
	20-34	26	27	20
	35-49	118	129	93
	50+	166	226	136
	Total HSDA:	317	389	253
FRASER NORTH	0-19	20	20	4
	20-34	109	110	94
	35-49	356	406	253
	50+	447	698	364
	Total HSDA:	932	1234	715
FRASER SOUTH	0-19	12	12	6
	20-34	100	102	76
	35-49	357	406	290
	50+	407	606	339
	Unknown	0	1	0
	Total HSDA:	876	1127	711
Total HA:		2125	2750	1679

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	39	39	14
	20-34	235	239	190
	35-49	831	941	636
	50+	1020	1530	839
	Unknown	0	1	0
Total HA:		2125	2750	1679

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	1605	2108	1297
Female	520	642	382

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	1679	49	608	35

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
FRASER Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
FRASER EAST	10 years or more	142	108
	5 years or more	88	69
	<5 years	87	76
	Total HSDA:	317	253
FRASER NORTH	10 years or more	453	333
	5 years or more	229	177
	<5 years	250	205
	Total HSDA:	932	715
FRASER SOUTH	10 years or more	390	305
	5 years or more	242	203
	<5 years	244	203
	Total HSDA:	876	711
Total HA:		2125	1679

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	985	746
5 years or more	559	449
<5 years	581	484
Total HA:	2125	1679

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries FRASER Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
FRASER EAST	126	397	45	82
FRASER NORTH	226	1379	63	275
FRASER SOUTH	202	1161	51	339
Total:	554	2937	159	696

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
FRASER EAST	182
FRASER NORTH	609
FRASER SOUTH	493
Total:	1284

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
VANCOUVER COASTAL Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	0-19	2	2	0
	20-34	21	21	20
	35-49	86	100	69
	50+	192	312	170
	Total HSDA:	301	435	259
RICHMOND	0-19	5	5	1
	20-34	22	22	16
	35-49	45	48	38
	50+	75	114	62
	Total HSDA:	147	189	117
VANCOUVER	0-19	56	59	7
	20-34	413	421	328
	35-49	1605	1878	1207
	50+	2379	3945	1903
	Total HSDA:	4453	6303	3445
Total HA:		4901	6927	3821

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	63	66	8
	20-34	456	464	364
	35-49	1736	2026	1314
	50+	2646	4371	2135
Total HA:		4901	6927	3821

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
	2	2	0
Male	4310	6091	3368
Female	589	834	453

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	3821	51	590	35

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
VANCOUVER COASTAL Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	10 years or more	170	141
	5 years or more	50	46
	<5 years	81	72
	Total HSDA:	301	259
RICHMOND	10 years or more	67	50
	5 years or more	39	31
	<5 years	41	36
	Total HSDA:	147	117
VANCOUVER	10 years or more	2223	1614
	5 years or more	1097	865
	<5 years	1133	966
	Never on ART	0	0
	Total HSDA:	4453	3445
Total HA:	4901	3821	

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	2460	1805
	5 years or more	1186	942
	<5 years	1255	1074
	Never on ART	0	0
Total HA:		4901	3821

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries
VANCOUVER COASTAL Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH SHORE/COAST GARIBALDI	140	365	56	94
RICHMOND	41	257	13	89
VANCOUVER	527	9746	205	5236
Total:	708	10368	274	5419

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH SHORE/COAST GARIBALDI	6
RICHMOND	1
VANCOUVER	99
Total:	106

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
VANCOUVER ISLAND Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	0-19	2	2	1
	20-34	23	25	18
	35-49	83	96	69
	50+	159	252	132
	Total HSDA:		267	375
NORTH VANCOUVER ISLAND	0-19	2	2	1
	20-34	13	14	9
	35-49	33	37	26
	50+	58	87	46
	Total HSDA:		106	140
SOUTH VANCOUVER ISLAND	0-19	9	9	2
	20-34	42	44	33
	35-49	218	256	177
	50+	377	591	300
	Total HSDA:		646	900
Total HA:		1019	1415	814

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	13	13	4
	20-34	78	83	60
	35-49	334	389	272
	50+	594	930	478
Total HA:		1019	1415	814

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	817	1140	657
Female	202	275	157

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	814	52	470	35

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
VANCOUVER ISLAND Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	10 years or more	129	103
	5 years or more	67	57
	<5 years	71	60
	Total HSDA:	267	220
NORTH VANCOUVER ISLAND	10 years or more	47	35
	5 years or more	25	18
	<5 years	34	29
	Total HSDA:	106	82
SOUTH VANCOUVER ISLAND	10 years or more	314	222
	5 years or more	168	142
	<5 years	164	148
	Total HSDA:	646	512
Total HA:		1019	814

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	490	360
	5 years or more	260	217
	<5 years	269	237
Total HA:		1019	814

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries
VANCOUVER ISLAND Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
CENTRAL VANCOUVER ISLAND	166	547	79	182
NORTH VANCOUVER ISLAND	113	233	47	74
SOUTH VANCOUVER ISLAND	182	1513	49	530
Total:	461	2293	175	786

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
CENTRAL VANCOUVER ISLAND	44
NORTH VANCOUVER ISLAND	28
SOUTH VANCOUVER ISLAND	86
Total:	158

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
NORTHERN Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH EAST	0-19	1	1	0
	20-34	4	5	1
	35-49	16	18	11
	50+	19	24	11
	Total HSDA:	40	48	23
NORTH WEST	0-19	1	1	0
	20-34	9	13	8
	35-49	27	39	22
	50+	30	45	22
	Total HSDA:	67	98	52
NORTHERN INTERIOR	0-19	5	5	4
	20-34	27	30	19
	35-49	69	86	57
	50+	74	120	62
	Total HSDA:	175	241	142
Total HA:		282	387	217

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	7	7	4
	20-34	40	48	28
	35-49	112	143	90
	50+	123	189	95
Total HA:		282	387	217

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	176	245	138
Female	106	142	79

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	217	47	500	35

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
NORTHERN Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH EAST	10 years or more	15	6
	5 years or more	12	7
	<5 years	13	10
	Total HSDA:	40	23
NORTH WEST	10 years or more	17	7
	5 years or more	27	23
	<5 years	23	22
	Total HSDA:	67	52
NORTHERN INTERIOR	10 years or more	52	35
	5 years or more	51	45
	<5 years	72	62
	Total HSDA:	175	142
Total HA:		282	217

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	84	48
	5 years or more	90	75
	<5 years	108	94
Total HA:		282	217

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries
NORTHERN Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH EAST	30	56	7	9
NORTH WEST	62	140	22	26
NORTHERN INTERIOR	97	384	25	182
Total:	189	580	54	217

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH EAST	5
NORTH WEST	20
NORTHERN INTERIOR	21
Total:	46

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

HA	HSDA	Alive	Ever treated with ARVs	Currently treated with ARVs
INTERIOR	EAST KOOTENAY	7	10	7
	KOOTENAY BOUNDARY	3	6	3
	OKANAGAN	16	29	8
	THOMPSON/CARIBOO/SHUSWAP	19	34	16
	Total HA:	45	79	34
FRASER	FRASER EAST	31	39	23
	FRASER NORTH	58	87	37
	FRASER SOUTH	67	93	54
	Total HA:	156	219	114
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBALDI	22	41	19
	RICHMOND	7	12	6
	VANCOUVER	501	779	424
	Total HA:	530	832	449
VANCOUVER ISLAND	CENTRAL VANCOUVER ISLAND	49	74	40
	NORTH VANCOUVER ISLAND	13	22	10
	SOUTH VANCOUVER ISLAND	33	70	28
	Total HA:	95	166	78
NORTHERN	NORTH EAST	11	13	6
	NORTH WEST	33	56	29
	NORTHERN INTERIOR	62	94	58
	Total HA:	106	163	93
Total:		932	1459	768

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	589	937	470
Female	343	522	298

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total:	768	48	460	35

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





5.1 Drug Names and Definitions

Abacavir (Ziagen, ABC): a NUCLEOSIDE ANALOG from ViiV Healthcare.

Active: persons in the HIV/AIDS Drug Treatment program that are prescribed one or more drugs in this current month

Amphotericin B (Fungilin): a drug used for treatment of candidiasis and other fungal infections.

Amprenavir (Agenerase, APV): a PROTEASE INHIBITOR from ViiV Healthcare.

Antiretroviral (ARV): a substance that stops or suppresses the activity of a retrovirus, such as HIV. NUCLEOSIDE ANALOGS and PROTEASE INHIBITORS are examples of antiretroviral drugs.

Atazanavir (Reyataz, ATV): a PROTEASE INHIBITOR from Bristol-Myers Squibb.

Atovaquone (Mepron): a medication used to treat pneumocystis carinii pneumonia and, in some cases, toxoplasmosis.

Atripla (ATP): the Bristol-Myers Squibb and Gilead trade name for a pill that contains EFAVIRENZ, TENOFOVIR and EMTRICITABINE.

Azithromycin (Zithromax): an antibiotic used for the prevention of mycobacterium avium complex (MAC) in people with advanced HIV infection.

Boosted PI: a combination therapy regimen of four or fewer antiretroviral drugs, including one PI and a small (400 mg or less, total daily dose) additional dose or RITONAVIR. The addition of RITONAVIR inhibits metabolism of other PIs and improves their exposure. This may allow for decreased dosing frequency or pill burden and may improve adherence and antiretroviral activity.

CD4 Cell Count: the most commonly used marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. Normal CD4 cell counts are greater than 800 per cubic millimeter of blood.

Chemokine Receptor Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV entry by blocking the binding site of co-receptors, such as CCR5 or CXCR4.

Clarithromycin (Biaxin): an antibiotic used for the treatment of mycobacterium avium complex (MAC). It is also used for preventing MAC in those with advanced HIV infection.

Combination Therapy: using at least two drugs simultaneously to more effectively combat a disease. Initial combination therapy for HIV contains at least three ANTIRETROVIRALS.

Combivir (CBV): the ViiV Healthcare trade name for a pill that contains both ZIDOVUDINE and LAMIVUDINE.

Complera (CPL): the Gilead and Janssen trade name for a pill that contains EMTRICITABINE, RILPIVIRINE and TENOFOVIR.

Darunavir (Prezista, DRV): a PROTEASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Deceased: persons enrolled in the HIV/AIDS Drug Treatment program that died in this time period.

Delavirdine (Rescriptor, DLV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Agouron/ViiV Healthcare.

Didanosine (Videx, DDI): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.





Dolutegravir (DTG): an INTEGRASE INHIBITOR from ViiV Healthcare that has demonstrated activity against HIV in treatment-experienced patients.

Efavirenz (Sustiva, EFV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Bristol-Myers Squibb.

Elvitegravir (EGV): an INTEGRASE INHIBITOR from Gilead Sciences that has demonstrated activity against HIV in treatment-experienced patients.

Emtricitabine (FTC): a nucleoside analog from Gilead Sciences. It is currently available as a component of TRUVADA.

Enfuvirtide (Fuzeon, T20): a FUSION INHIBITOR from Hoffman-La Roche that targets the gp41 protein on the surface of HIV. It is administered as a subcutaneous injection.

Entry Inhibitor: a drug that inhibits the entry of HIV into cells. Entry inhibitors include FUSION INHIBITORS, CHEMOKINE RECEPTOR INHIBITORS, and attachment inhibitors.

Etravirine (ETV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Ethambutol (Myambutol): an antibiotic used in COMBINATION THERAPY for treatment of mycobacterial infections such as tuberculosis and mycobacterium avium complex (MAC).

Famciclovir (Famvir): a PRODRUG for an acyclovir-like active compound. It is an approved therapy for shingles and recurrent outbreaks of herpes simplex-2.

First started program: a person prescribed their first regimen ever in the HIV/AIDS drug treatment program.

Fosamprenavir (Telzir, fAPV): a PROTEASE INHIBITOR from ViiV Healthcare. Fosamprenavir is a PRODRUG of AMPRENAVIR.

Fusion Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV from fusing with and thereby infecting CD4 cells.

Granulocyte Colony Stimulating Factor (GCSF, Neupogen): a natural hormone that stimulates production of granulocytes, a type of white blood cell (leukocyte).

Health Authority: refers to the five (Interior, Fraser, Northern, Vancouver Coastal, Vancouver Island) health authorities created by the BC Ministry of Health.

Inactive: persons no longer prescribed drugs through the HIV/AIDS Drug Treatment program this current month.

Indinavir (Crixivan, IDV): a PROTEASE INHIBITOR from Merck.

Integrase Inhibitor: a drug that blocks integrase, a protein that HIV needs to enter cells and produce copies of itself, from working.

Kivexa (KIV): the ViiV Healthcare's trade name for a pill that contains both ABACAVIR and LAMIVUDINE.

Lamivudine (3TC): a NUCLEOSIDE ANALOG from ViiV Healthcare with activity against HIV and hepatitis B.

Lopinavir (Kaletra, LPV/r): a PROTEASE INHIBITOR from Abbott Laboratories. Kaletra is a combination of lopinavir and a low dose of RITONAVIR, a drug that improves blood levels of lopinavir.

Maraviroc (MVC, Celsentri): a CHEMOKINE RECEPTOR INHIBITOR from ViiV Healthcare that inhibits HIV entry by blocking the binding site of the CCR5 co-receptor.





Median (MED) age: median age of participants in the HIV/AIDS Drug Treatment program in that time period.

MDRT: see MULTIPLE DRUG RESCUE THERAPY

Moved out of BC: a person in the HIV/AIDS Drug Treatment program that is no longer in the program, because they moved out of BC in this time period.

Moxifloxacin: a fluoroquinolone antibiotic that is used for treatment of mycobacterium avium complex which is resistant to clarithromycin.

Multiple Drug Rescue Therapy (MDRT or Mega-HAART): the use of five or more antiretrovirals to treat HIV, typically some or all of which have been used previously by the individual.

Nelfinavir (Viracept, NFV): a PROTEASE INHIBITOR from ViiV Healthcare.

Net change: the net increase or decrease in persons enrolled in the HIV/AIDS Drug Treatment Program from the previous time period.

Nevirapine (Viramune, NVP): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Boehringer Ingelheim.

NNRTI: see NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR.

NNRTI / no PI: a combination therapy regimen of four or fewer antiretroviral drugs, including an NNRTI, but no PIs.

Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI): a member of a class of compounds, including DELAVIRDINE, NEVIRAPINE, EFAVIRENZ and ETRAVIRINE that acts to directly combine with and block the action of HIV's reverse transcriptase enzyme.

NRTI: see NUCLEOSIDE ANALOG.

Nucleoside Analog (Nucleoside Analog Reverse Transcriptase Inhibitor, NRTI): a type of ANTIVIRAL drug, such as AZT (ZIDOVUDINE), ddI (DIDANOSINE) or 3TC (LAMIVUDINE), whose structure constitutes a defective version of a natural nucleoside. Nucleoside analogs may take the place of the natural nucleosides, blocking the completion of a viral DNA chain during infection of a new cell by HIV. The HIV enzyme reverse transcriptase is more likely to incorporate nucleoside analogs into the DNA it is constructing than is the DNA polymerase that cells normally use for DNA construction.

Nucleotide Analog: ANTIVIRAL compounds such as TENOFOVIR that function exactly like NUCLEOSIDE ANALOGS but are pre-activated through the addition of a phosphate group during their synthesis. This phosphorylation is supposed to enhance the drug levels and activity achieved within cells.

Octreotide Acetate (Sandostatin): a drug used to treat chronic refractory diarrhea.

One or more PI: a combination therapy regimen of four or fewer antiretroviral drugs, including one unboosted PI or 2 or more PIs with or without a small (400 mg or less, total daily dose) additional dose of RITONAVIR.

Other: an antiretroviral regimen in the HIV/AIDS Drug Treatment program other than NNRTI/no PI, boosted PI, 1 or more PIs or MDRT-based regimens (eg. Triple Nucleoside regimens).

Paromomycin (Humatin): an antibiotic used to treat infections caused by intestinal parasites, including AIDS-related cryptosporidiosis.

Pentamidine: an antiprotozoal drug used in aerosol form as a preventative against pneumocystis carinii pneumonia (PCP).





PI: see PROTEASE INHIBITOR.

Prezcobix (PZC): the Janssen trade name for a pill that contains DARUNAVIR and COBICISTAT.

Prodrug: a compound that is converted within the body into the active form that has medical effects.

Protease Inhibitor: a drug that binds to and blocks HIV protease from working, thus preventing the production of new functional viral particles.

Raltegravir (RGV, Isentress): an INTEGRASE INHIBITOR from Merck that has activity against HIV in treatment-experienced patients.

Restarted/ changed therapy (Tx): a person in the HIV/AIDS Drug Treatment program that was either CURRENTLY OFF THERAPY and now has been prescribed a new regimen or a person who has changed regimens.

Rifabutin (Mycobutin): an oral drug used to prevent mycobacterium avium complex (MAC) in people with advanced HIV infection. Rifabutin is also used in combination with other drugs for the treatment of active MAC infections.

Rilpivirine (Edurant): a NON-NUCELOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Janssen.

Ritonavir (Norvir, RTV): a PROTEASE INHIBITOR from Abbott. Ritonavir is commonly used to inhibit the liver enzyme metabolism of other protease inhibitors and improve their blood exposure.

Saquinavir (Invirase, SQV): a PROTEASE INHIBITOR from Hoffman-La Roche.

Stavudine (Zerit, d4T): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Stopped all therapies (Tx): a person in the HIV/AIDS Drug Treatment program that stopped all therapies in this time period and is now CURRENTLY OFF THERAPY.

Stribild (STR): the Gilead trade name for a pill that contains ELVITEGRAVIR, COBICISTAT, EMTRICITABINE and TENOFOVIR.

Tenofovir (Viread, TDF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV and hepatitis B.

Tipranavir (Aptivus, TPV): a PROTEASE INHIBITOR from Boehringer Ingelheim that has activity against HIV in treatment-experienced patients.

Triple Therapy: the use of three drugs, most often a PROTEASE INHIBITOR or NON-NUCLEOSIDE ANALOG with two NUCLEOSIDE ANALOGS, in the treatment of HIV.

Triumeq (TRQ): the ViiV Healthcare's trade name for a pill that contains DOLUTEGRAVIR, ABACAVIR and LAMIVUDINE.

Trizivir (TRZ): the ViiV Healthcare's trade name for a pill that contains ABACAVIR, ZIDOVUDINE and LAMIVUDINE.

Truvada (TRU): the Gilead trade name for a pill that contains TENOFOVIR and EMTRICITABINE.

Valganciclovir: an antiviral drug used to treat cytomegalovirus (CMV) retinitis.

Viral Load: the amount of HIV RNA per unit of blood plasma. An indicator of virus concentration and reproduction rate. HIV viral load is employed as a measure of the success of antiretroviral therapy.

Zidovudine (Retrovir, AZT): a NUCLEOSIDE ANALOG from ViiV Healthcare. AZT is also approved for preventing maternal-fetal HIV transmission.

